Agilent alleges that Twist CEO Emily Leproust and other employees stole trade secrets from it. A trial date has been set for Feb. 24, 2020.
Agilent said it has uncovered new and relevant facts in its intellectual property lawsuit against Twist and its Founder and CEO Emily LeProust.
The financing will support growth in Maravai's three life science segments: bioprocess impurity testing, oligonucleotide synthesis, and protein detection.
IDT will operate as a standalone company within Danaher's Life Sciences segment after the close of the deal, which is expected to occur in mid-2018.
The company will integrate the oligonucleotide manufacturer with two of its existing sections to form a new Nucleic Acid Chemistry business unit.
The acquisition of GeneWorks' oligo business widens IDT's reach in the Asia-Pacific region, the company said.
Agilent filed a lawsuit against Twist nearly a year ago, alleging that Twist Cofounder and CEO Emily LeProust had stolen DNA oligonucleotide synthesis technology.
Scientists led by Eric Kmiec showed that their strategy of point mutation editing with single-stranded DNA oligos and double-strand breaks works with CRISPR/Cas9.
Single nucleus sequencing analysis of triple-negative breast tumors indicated that copy number changes occur in bursts early in tumor evolution.
In its court filing, the company said Twist Founder and CEO Emily LeProust stole its technology and breached her confidentiality agreements.
Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.
St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.
St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.
In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.